Skip to content

Efficacy of etidronate and sequential monofluorophosphate in severe postmenopausal osteoporosis: A pilot study

by J. D. Ringe, A. Dorst, H. Faber, C. Kipshoven, L. C. Rovati, I. Setnikar
Rheumatology International ()
Get full text at journal


In a three-year pilot study on 52 women with severe postmenopausal osteoporosis, treatment with etidronate followed by calcium and vitamin D (ECaD) was compared to etidronate followed by monofluorophosphate, calcium and vitamin D (EFCaD). BMD in lumbar spine, total hip and femoral neck increased significantly more with EFCaD than with ECaD. Pain-mobility score decreased significantly more with EFCaD than with ECaD (p=0.006). New vertebral fractures occurred in three patients under EFCaD (12%) and in nine under ECaD (35%), (p=0.048). Three patients under EFCaD (12%) and 15 under ECaD (58%) did not respond to therapy (p of difference=0.001). Mild or moderate adverse reactions were reported by 25 patients, with no significant difference between the two groups. The pilot study suggests that etidronate, sequentially followed by monofluorophosphate, could be a safe, effective and relatively inexpensive therapy in severe postmenopausal osteoporosis.

Cite this document (BETA)

Readership Statistics

10 Readers on Mendeley
by Discipline
100% Medicine and Dentistry
by Academic Status
40% Student > Bachelor
20% Researcher
10% Professor > Associate Professor

Sign up today - FREE

Mendeley saves you time finding and organizing research. Learn more

  • All your research in one place
  • Add and import papers easily
  • Access it anywhere, anytime

Start using Mendeley in seconds!

Sign up & Download

Already have an account? Sign in